OMEDIT Île-de-France

What OMEDIT Île-de-France does

OMEDIT Île-de-France is a regional public health observatory operating within France's national OMEDIT network, mandated to support healthcare professionals in the Île-de-France region on the proper use of medicines, medical devices, and therapeutic innovations. Rather than a commercial enterprise, it functions as an advisory and resource body, providing regulatory monitoring, professional training programs, practical toolboxes, and analytical reports to hospitals, clinics, and healthcare establishments across the region.

Its core deliverables include regulatory surveillance outputs, guidance documents, and training curricula, distributed primarily through its website and institutional partnerships. A website redesign was completed in March 2025, modernizing the dissemination layer, although disclosed audience metrics (0 newsletter subscribers, 0 LinkedIn followers) indicate limited external traction to date. The organization maintains operational linkages with major national health authorities — HAS, ANSM, DGOS, ANS — and with the CNAM, while partnering with AP-HP as the principal regional hospital network for downstream delivery.

The business model is fully public: OMEDIT Île-de-France is funded by ARS Île-de-France (the Regional Health Agency) and operates with 13 employees. There is no disclosed commercial pricing, subscription product, or third-party revenue stream. Its AI-related activity is confined to participation in the DGOS-led AMI program exploring AI applications for pharmaceutical inventory management, with no proprietary models or in-house ML capability disclosed.

Name

OMEDIT Île-de-France

Legal name

Observatoire du Médicament, des Dispositifs médicaux et de l'Innovation Thérapeutique

Website

https://omedit-idf.fr

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

OMEDIT Île-de-France is a regional public health observatory that supports healthcare professionals in Île-de-France with regulatory monitoring, training, and practical tools on medicines, medical devices, and therapeutic innovation.

Ownership category

akta.pro rank

Product category

Public Health Observatory / Medication Regulatory Services

NAICS

Administration of Public Health Programs (92312), Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615)

akta.pro primary industry

Regulatory Affairs, Labeling & Advertising/Promotion Compliance (HLAJADAI)

akta.pro secondary industries

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Drug Regulators (Human Pharmaceuticals) (HLAJADAA), Medical Device Regulators (HLAJADAC)

Keywords

• Medication regulatory monitoring
• Healthcare professional training
• Clinical pharmacy resources
• Public health observatory
• Drug safety guidance

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels2 records

Marketing channels5 records

Core offering

OMEDIT Île-de-France is a regional public health observatory that delivers daily scientific and regulatory monitoring on medications, medical devices, and therapeutic innovations to healthcare professionals and establishments in the Île-de-France region. It translates regulatory updates into practical toolboxes, training programs, regional projects, and thematic guidance covering biosimilar substitution, medication reconciliation, clinical pharmacy, drug shortages, certification HAS, and sustainable healthcare practices.

Product overview

OMEDIT Île-de-France (Observatoire du Médicament, des Dispositifs médicaux et de l'Innovation Thérapeutique) is a regional healthcare observatory serving Île-de-France. The organization operates as a unified platform providing scientific and regulatory monitoring services, practical toolboxes, professional training, and regional healthcare coordination. The portfolio consists of a daily veille (monitoring) service, themed content sections, training programs including e-learning modules and in-person sessions, practical resource toolboxes, regional project coordination, and newsletter communications. The organization focuses on medication safety, clinical pharmacy, biosimilar substitution, medication reconciliation, and sustainable healthcare practices.

Differentiator

Problem solved

Functional benefit

Brands

• Plan Health Faire: Collaborative workshop on sustainable development applied to health, developed by Assistance Publique - Hôpitaux de Paris and OMEDIT Île-de-France
• Boîtes à outils

Products and services

• Veille scientifique et réglementaire (Daily Scientific and Regulatory Monitoring) Daily publication of curated regulatory and scientific updates on medications (e.g. biosimilars, RCP changes), medical devices and therapeutic innovations, intended for healthcare professionals and establishments in Île-de-France.
• Boîtes à outils (Practical Toolboxes) Collection of practical tools and resources organized by theme (medications and heat, biosimilars, clinical pharmacy, medication management), accessible to healthcare professionals.
• Formations (Training Programs) Training programs (in-person and webinar) for healthcare professionals, covering medication reconciliation, clinical pharmacy, medication and disability, and related regulatory and practice topics.
• Travaux régionaux (Regional Work and Projects) Regional projects including commissions, working groups, regional days, calls for projects, surveys, and communications for Île-de-France health establishments.
• Newsletter (OMEDIT Île-de-France Newsletter) Email newsletter service delivering news updates and event notifications to subscribers from the healthcare community.
• Thématiques (Thematic Content Platform) Web-based thematic content platform covering good use of health products, quality and risk management, financing and efficiency, patient pathways, sustainable development, and digital health contracting.
• Plan Health Faire (Sustainable Healthcare Workshop Initiative) Collaborative educational initiative (workshop and resources) on sustainable development applied to healthcare, co-developed with AP-HP, CHU de Poitiers and Université de Poitiers.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered core and minor.

• Haute Autorité de Santé (HAS)coreStrategic or Co-development Partner · 1 January 2026OMEDIT Île-de-France collaborates with HAS on regional events and webinars, including the PAAM webinar featuring STARAQS and the 2026 Regional (de)prescription Day.
• ARS Île-de-FrancecoreStrategic or Co-development Partner · 1 January 2026ARS Île-de-France is the governing authority for OMEDIT Île-de-France and coordinates regional health initiatives including calls for projects on AI in pharmacy management and Centres Experts de Prévention et de Prise en charge de l'Iatrogénie Médicamenteuse (CEPPIM).
• DGOS (Direction Générale de l'Offre de Soins)minorStrategic or Co-development Partner · 1 January 2026DGOS launched an AMI (Appel à manifestation d'intérêt) on AI potential for inventory management, dispensing, and administration in healthcare, coordinated with regional health agencies.
• Assistance Publique - Hôpitaux de Paris (AP-HP)coreStrategic or Co-development Partner · 1 January 2025AP-HP co-created Plan Health Faire with OMEDIT Île-de-France, a collaborative workshop aimed at helping healthcare actors understand and act on sustainable development issues applied to healthcare. This initiative helps healthcare professionals pass sustainable practices into their facilities.
• CHU de PoitierscoreStrategic or Co-development Partner · 1 January 2025CHU de Poitiers co-created Plan Health Faire with OMEDIT Île-de-France, contributing to the development of sustainable healthcare training and resources.
• Université de PoitierscoreStrategic or Co-development Partner · 1 January 2025Université de Poitiers is involved in Plan Health Faire initiative alongside OMEDIT Île-de-France and CHU de Poitiers, providing academic expertise in sustainable healthcare practices.
• Caisse Nationale d'Assurance Maladie (CNAM)coreStrategic or Co-development Partner · 1 January 2025CNAM partnered with OMEDIT Île-de-France to produce a memo on good practices for biosimilar substitution in pharmacies. This guidance document synthesizes regulatory requirements, best practices, and useful links for all actors involved in biosimilar substitution.
• Agence du Numérique en Santé (ANS)minorStrategic or Co-development Partner · 1 January 2025ANS partnered with DNS (Délégation au numérique en santé) to launch the 'Adoption des Innovations' call for projects to co-finance usage studies for innovative digital solutions in the medico-social sector.

Recent moves5 records

Expansion highlights3 records

Regional players

• OMEDIT PACA: Regional drug/medical-device observatory covering the Provence-Alpes-Côte d'Azur region. Directly comparable as a sibling OMEDIT body with identical mandate (medication, medical device, therapeutic innovation guidance) and ARS affiliation, but serving a different French region.
• OMEDIT Centre-Val de Loire: Regional observatory of medication and medical devices in the Centre-Val de Loire region. Same national OMEDIT network, same regulatory-cooperation mandate, parallel institutional structure under its regional ARS.

Others

• ARS Île-de-France: The Regional Health Agency that governs and funds OMEDIT IDF. Comparable as the institutional counterparty that defines regional health priorities (CEPPIM, AI pharmacy AMI, eco-responsible care) within which OMEDIT IDF operates; not a direct peer but the parent authority shaping its mandate.
• CNAM (Caisse Nationale d'Assurance Maladie): National health insurance fund that co-produced OMEDIT IDF's biosimilar substitution memo. Comparable as a national payer/regulator whose guidance OMEDIT IDF operationalizes regionally, particularly on prescription quality and biosimilar substitution.

Broad incumbents

• Haute Autorité de Santé (HAS): National health authority issuing good-practice guidelines, certification frameworks (e.g., HAS 2027) and health technology assessments. OMEDIT IDF is a regional dissemination partner of HAS; HAS is a broader incumbent producing the upstream guidance OMEDIT IDF translates for Île-de-France professionals.
• ANSM (Agence nationale de sécurité du médicament): National French drug and medical-device regulator. Comparable as the apex authority on the same medication/medical-device regulatory topics OMEDIT IDF disseminates regionally, but operates nationally and with statutory regulatory power rather than as a regional observatory.
• DGOS (Direction Générale de l'Offre de Soins): National directorate within the French Ministry of Health that issues AMIs and national guidance on hospital pharmacy and medication management. Overlaps with OMEDIT IDF's mandate as the upstream national authority whose calls (e.g., 2026 AI-in-pharmacy AMI) OMEDIT IDF channels to regional establishments.

Emerging players

• SFPC (Société Française de Pharmacie Clinique): National learned society for clinical pharmacy that co-conducted OMEDIT IDF's 2025 psychiatry clinical pharmacy survey. Comparable because both produce clinical-pharmacy practice guidance and training resources for French pharmacists, but SFPC operates as a professional society rather than a public observatory.
• STARAQS: Structure Régionale d'Appui à la Qualité et à la Sécurité en santé, featured alongside OMEDIT IDF and HAS in the 2026 PAAM webinar. Comparable as a regional healthcare quality/safety support body in Île-de-France with overlapping audience of health establishments and quality professionals.
• Réseau PIC: French clinical pharmacy innovation network collaborating with OMEDIT IDF on the 2025 psychiatry pharmacy survey. Comparable as a thematic network working on clinical pharmacy practice improvement, partially overlapping OMEDIT IDF's training and survey function.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/omedit-ile-de-france

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OMEDIT Île-de-France